ReviewThe Journal of clinical investigation2006
Going nuclear in metabolic and cardiovascular disease.
Review in The Journal of clinical investigation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Article
- Regulation of Epigenetic Modifications in the Placenta during Preeclampsia: PPARγ Influences H3K4me3 and H3K9ac in Extravillous Trophoblast Cells.International journal of molecular sciences · 2021Article
- Myeloid-specific deficiency of pregnane X receptor decreases atherosclerosis in LDL receptor-deficient mice.Journal of lipid research · 2020Article
- Angiotensin II type 2 receptor stimulation with compound 21 improves neurological function after stroke in female rats: a pilot study.American journal of physiology. Heart and circulatory physiology · 2019Article
- Brain activity of anandamide: a rewarding bliss?Acta pharmacologica Sinica · 2019Review
- Nuclear receptors in vascular biology.Current atherosclerosis reports · 2015Review
- Prenatal Hypoxia Reduces Mitochondrial Protein Levels and Cytochrome c Oxidase Activity in Offspring Guinea Pig Hearts.Reproductive sciences (Thousand Oaks, Calif.) · 2014Article
- Role of human pregnane X receptor in high fat diet-induced obesity in pre-menopausal female mice.Biochemical pharmacology · 2014Article
- Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.Pharmacology & therapeutics · 2013Review
- The G32E functional variant reduces activity of PPARD by nuclear export and post-translational modification in pigs.PloS one · 2013Article
- Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease.Pharmacological reviews · 2012Review
- Suppression of ERR targets by a PPARα/Sirt1 complex in the failing heart.Cell cycle (Georgetown, Tex.) · 2012Article
- Article
- Selected Extracts of Chinese Herbal Medicines: Their Effect on NF-κB, PPARα and PPARγ and the Respective Bioactive Compounds.Evidence-based complementary and alternative medicine : eCAM · 2012Article
- Altered mitochondrial apoptotic pathway in placentas from undernourished rat gestations.American journal of physiology. Regulatory, integrative and comparative physiology · 2011Article
- PPARα-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway.Cell metabolism · 2011Article
- Structural basis for iloprost as a dual peroxisome proliferator-activated receptor alpha/delta agonist.The Journal of biological chemistry · 2011Article
- Deficiency of PXR decreases atherosclerosis in apoE-deficient mice.Journal of lipid research · 2011Article
- Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARγ agonist.The Biochemical journal · 2011Article
- 17β-Estradiol inhibition of PPARγ-induced adipogenesis and adipocyte-specific gene expression.Acta pharmacologica Sinica · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Estrogen receptors, PPARs, and liver X receptors are members of the nuclear receptor superfamily of ligand-dependent transcription factors that regulate diverse aspects of development and homeostasis. Recent studies of the biologic roles of these receptors and their mechanisms of action have significantly advanced our understanding of transcriptional programs that control lipid and carbohydrate metabolism, immunity and inflammation, and wound repair. These findings provide insights into the therapeutic actions of existing drugs that target nuclear receptors and raise new possibilities for development of safer, more effective drugs for the prevention and treatment of metabolic and cardiovascular diseases. In this introduction to this Review series, underlying mechanisms that enable nuclear receptors to positively and negatively regulate gene expression are presented as background to the focused reviews on estrogen receptors, PPARs, liver X receptors, and the PPARgamma coactivator-1 (PGC-1) family of coactivators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.